Elekta AB (OTCMKTS:EKTAY) Short Interest Up 154.7% in May

Posted by on Jun 13th, 2026

Elekta AB (OTCMKTS:EKTAY – Get Free Report) was the target of a significant growth in short interest in May. As of May 29th, there was short interest totaling 1,732 shares, a growth of 154.7% from the May 14th total of 680 shares. Based on an average daily volume of 3,159 shares, the short-interest ratio is currently 0.5 days. Approximately 0.0% of the shares of the stock are sold short.

Elekta Trading Up 0.9%

Shares of EKTAY traded up $0.05 during trading hours on Friday, hitting $5.56. The company had a trading volume of 1,890 shares, compared to its average volume of 1,935. The firm has a market cap of $2.05 billion, a P/E ratio of -34.75 and a beta of 1.00. The stock’s 50 day moving average price is $5.96 and its 200 day moving average price is $6.06. The company has a quick ratio of 0.73, a current ratio of 0.95 and a debt-to-equity ratio of 0.56. Elekta has a 52-week low of $4.35 and a 52-week high of $6.93.

Elekta (OTCMKTS:EKTAY – Get Free Report) last released its quarterly earnings data on Thursday, May 28th. The company reported $0.06 EPS for the quarter. The firm had revenue of $521.00 million for the quarter. Elekta had a positive return on equity of 10.67% and a negative net margin of 3.32%. On average, research analysts predict that Elekta will post 0.43 EPS for the current year.

Analysts Set New Price Targets

Separately, Zacks Research downgraded Elekta from a “hold” rating to a “strong sell” rating in a report on Tuesday, June 2nd. Two analysts have rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Get Our Latest Analysis on EKTAY

About Elekta

(Get Free Report)

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.

Read More

Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.